Donanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. Donanemab was developed by Eli Lilly and Company. From Wikipedia
The TGA has approved the groundbreaking drug for early-stage Alzheimer’s patients, offering hope for slowing cognitive decline, though high costs and safety protocols limit access.
